| LONZA N | 550.40 / -1.08% |
| Date/Time | 04/20 / 17:31 |
| Chg. / Chg.(%) | -6.00 / -1.08% |
| Bid | - / 129 |
| Ask | - / 113 |
| Open | 557.60 |
| Previous Close | 556.40 |
| High | 560.00 |
| Low | 548.40 |
| Volume [CHF] | 77,600,146.50 |
| Volume [Units] | 140,659 |
| Price fixings | 4504 |
| ISIN | CH0013841017 |
| Security | LONN |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
| Bid Size | Bid | Ask | Ask size |
|---|---|---|---|
| 129 | - | - | 113 |
| 10 | 555.00 | 556.00 | 250 |
| 80 | 551.00 | 560.00 | 22 |
| 36 | 549.00 | 563.00 | 69 |
| 54 | 548.00 | 564.00 | 144 |
| 100 | 547.40 | 565.00 | 916 |
| 9 | 547.00 | 565.20 | 100 |
| 25 | 546.00 | 566.00 | 100 |
| 100 | 545.80 | 567.00 | 70 |
| 75 | 545.20 | 567.40 | 100 |
News
- aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
04/14/2021 / 14:00 - GlobeNewswire - Arbor Biotechnologies Names Devyn Smith, Ph.D., as CEO
04/01/2021 / 14:00 - GlobeNewswire - Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
03/12/2021 / 07:00 - GlobeNewswire - Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors
03/03/2021 / 14:00 - GlobeNewswire - Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire
Real-time